Ascendia Pharmaceutical Solutions

#DCATweek 2025 is off to a great start for the Ascendia Pharmaceutical Solutions team, including Founder and CEO Jim Jingjun Huang, Ph.D., Chief Business Officer Robert Bloder and Sr. Director, Business Development Jared Hahn. If you need a #CDMO partner for your #drugdevelopment project and are in New York, contact us at ?[email protected] so we can schedule a meeting.

In the world of #PharmaceuticalInnovation, the challenge of poor #solubility in #NewChemicalEntities (#NCEs) continues to shape #DrugDevelopment strategies. With nearly 90% of drugs in the #DevelopmentPipeline classified as poorly soluble, the need for effective #FormulationTechnologies has never been greater. One breakthrough solution that has garnered significant attention is #nanosuspension technology—an advanced approach to enhancing #DrugSolubility, #bioavailability, and overall #therapeutic #efficacy. Ascendia Pharmaceutical Solutions?stands at the forefront of this innovation, offering cutting-edge nanosuspension capabilities that address the most pressing challenges in #DrugFormulation. In this article published in?Drug Development & Delivery, Shaukat Ali, PhD, Senior Director of Scientific Affairs and Technical Marketing, and Jim Jingjun Huang, Ph.D., Founder and CEO, delve into the transformative impact of nanosuspension technology and its broad applicability across multiple routes of administration, including #oral, #injectable, #ocular, #pulmonary, and #Topical #DrugDelivery. Click here to read on: https://lnkd.in/gV3qCzqi

Please join Ascendia Pharmaceutical Solutions on Wednesday, March 26, at 1:30PM for a webinar entitled “Long acting PLGA complex parenterals and IVIVC development” presented by Shaukat Ali, PhD, senior director of scientific affairs and technical marketing at Ascendia, and Prof. Diane Burgess, PhD, founder of DIANT Pharma.?The webinar is being presented by PharmTech, an MJH Life Sciences??brand. Dr. Ali and Dr. Burges will discuss multiple topics, including?poly(lactic-co-glycolic) acid (#PLGA) and its application in the development of long-acting injectables (#LAI).?They will provide insight into the development of in vitro-in vivo correlations (IVIVCs) and in vitro-in vivo relationships (IVIVRs) for complex?#injectables.?A?deep dive in PLGA’s chemistry and its drug release phenomenon?will also be given during?the webinar. Learn more about the webinar and register here: https://lnkd.in/egra7Zxs #drugdevelopment #pharmaceuticals

We are less than one week from DCAT (Drug, Chemical & Associated Technologies Association) Week. If you’ll be in New York City, schedule a meeting with Ascendia Pharmaceutical Solutions CEO Jim Jingjun Huang, Ph.D. and CBO Robert Bloder to discuss how we can be your CDMO of Choice for your drug development projects. Our team is eager to learn about your pipeline and how our four proprietary nanotechnologies and state-of-the-art manufacturing can help you advance formulation development and guide your drug through to commercialization Book your meeting with us at the InterContinental New York Barclay Hotel now by emailing [email protected] We look forward to meeting you!

We are less than one month away from #Interphex2025, the leading global pharmaceutical and biotechnology conference, and we are thrilled to have Ascendia’s Sr. Director of Scientific Affairs and Technical Marketing Dr. Shaukat Ali presence on various panels!? Dr. Ali will be a speaker on a panel that will discuss the impact of long-acting injectables (#LAI) and implants in reducing dosing frequency. They will also talk about how LAIs make treatments more tolerable, inherently leading to better adherence, and ultimately better outcomes. ??? Date: April 1- 3, 2025?? ??Location: Javits Center, New York ?? Register today: https://bit.ly/4h2Qc2M? He will also be a moderator on four Quick Fire discussions:? - Recent Breakthrough in Predicting Tabletability of Mixtures - Tuesday, Apr 1 at 3:00 PM? - Operational Readiness in Radiopharmaceutical Production – Tuesday, Apr 1 at 3:15 PM??? - Improve Drug Efficacy and Reliability Using Temperature Trend Analysis - Tuesday, Apr 1 at 3:30 PM??? - PUPSIT Considerations with Sterile Filtration Solutions –? Tuesday, Apr 1 at 3:45 PM?? #drugdevelopment #Ascendia #Interphex #PharmaConference??

DCAT (Drug, Chemical & Associated Technologies Association) is right around the corner and Ascendia Pharmaceutical Solutions is thrilled to be attending once again on March 17-20 in New York City! We are eager to meet with you to explain the Ascendia Difference and how our four proprietary nanotechnologies can help you meet your drug development and formulation project needs. Schedule a meeting at the InterContinental New York Barclay Hotel with Ascendia CEO Jim Jingjun Huang, Ph.D. and CBO Robert Bloder to learn more about how Ascendia can be your #PartnerofChoice: https://lnkd.in/e6DdRwAT #Ascendia #DCATWeek #DCAT

In the world of #pharmaceutical innovation, the need for precise and efficient #DrugDeliverySystems is paramount. At Ascendia Pharmaceutical Solutions, we are proud to lead the way in #nanosuspension #FormulationDevelopment and manufacturing services, leveraging the sophisticated Ascendia’s #Nanomilling technology. This customized state-of-the-art equipment made by NETZSCH Group allows us to cater Ascendia’s #NanoSol? technology to complex nanosuspension pharmaceutical needs, providing scalable, high-quality solutions for #DrugDevelopment. Click the link here to look through our capabilities and the advantages we bring to the table: https://lnkd.in/gCKTU2M8

DCAT is less than a month away. Look forward to meeting Ascendia’s current and future CDMO clients and PE investors.

Reserve a spot to meet with Ascendia leaders Jim Jingjun Huang, Ph.D. and Robert Bloder at DCAT. Bring us your challenging drug and we will deliver a formulation ready for the clinic and beyond. Ascendia's advanced formulation technologies employ GRAS excipients to overcome poor solubility and bioavailability for parenteral, topical, and oral drug delivery.

Ascendia Pharmaceutical Solutions continues the expansion of its new business development team. Matthew Maki has joined one of the premier #pharmaceutical CDMOs as business development leader. Matt brings 15 years of experience in the #CDMO and Contract Analytical industries to Ascendia. In his career, Matt has supported small and large molecules from early-phase research to full-scale commercial manufacturing for several dosage forms. To learn more about Matt, the expanding new business development team, and how they are offering the Ascendia Difference to #drugdevelopment teams, read our story - ttps://https://lnkd.in/eTRb9hHp